Arch Therapeutics (OTCMKTS:ARTH) has been assigned a $3.00 price objective by equities researchers at HC Wainwright in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.

Separately, Zacks Investment Research downgraded Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Arch Therapeutics has a consensus rating of “Hold” and a consensus price target of $1.75.

Shares of Arch Therapeutics stock opened at $0.40 on Monday. Arch Therapeutics has a 1-year low of $0.25 and a 1-year high of $0.89.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.

Recommended Story: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.